Document:

Form of Voting Agreement

 Exhibit 10.1 
 FORM OF VOTING AGREEMENT 
 This VOTING AGREEMENT (this “Agreement”), dated as of
July 23, 2006, is entered into between Advanced Micro Devices, Inc., a Delaware corporation (“Parent”), and              (the
“Securityholder”). 
 WHEREAS, in order to induce Parent to enter into an Acquisition Agreement, dated as of the date hereof
(the “Acquisition Agreement”), among Parent, ATI Technologies Inc., a corporation continued under the laws of Canada (the “Company”), and 1252986 Alberta ULC, an unlimited liability company formed under the laws of
Alberta, relating to the acquisition of all of the outstanding common shares in the capital of the Company (“Common Shares”) pursuant to a Plan of Arrangement under Section 192 of the Canada Business Corporations Act in the
form attached as Exhibit B to the Acquisition Agreement (the “Plan of Arrangement”), Parent has requested that the Securityholder, and the Securityholder has agreed to, enter into this Agreement with respect to all Common Shares
(“Common Shares”), options to purchase Common Shares (“Options”) and restricted share units relating to Common Shares (“RSUs”) that the Securityholder beneficially owns or hereafter acquires
beneficial ownership of (such Shares, Options and RSUs, collectively, “Securities”). 
 NOW, THEREFORE, the parties hereto
agree as follows: 
 ARTICLE 1 
 GRANT OF PROXY; VOTING AGREEMENT 
 Section 1.01. Voting Agreement. The Securityholder hereby agrees to vote
or exercise its right to consent with respect to all Securities that the Securityholder is entitled to vote at the time of any vote in favor of approving the Plan of Arrangement at any meeting of the securityholders of the Company, and at any
adjournment or postponement thereof, at which the Plan of Arrangement (or any amended version thereof), are submitted for the consideration and vote of the securityholders of the Company in accordance with the Acquisition Agreement. The
Securityholder hereby agrees that, for so long as this Agreement is in effect, it will not vote any Securities in favor of, or consent to, and will vote the Securities it is entitled to vote against and not consent to, the approval of any
(i) Acquisition Proposal, (ii) reorganization, recapitalization, liquidation or winding-up of the Company or any other extraordinary transaction involving the Company, or (iii) corporate action the consummation of which would
frustrate the purposes, or prevent or delay the consummation of, the transactions contemplated by the Acquisition Agreement, in each case other than pursuant to the transactions contemplated by the Acquisition Agreement. 
 Section 1.02. Irrevocable Proxy. The Securityholder hereby revokes any and all previous proxies granted with respect to the
Securities. By entering into this Agreement, the Securityholder hereby grants a proxy appointing Parent as the Securityholder’s attorney-in-fact and proxy, with full power of substitution, for and in the Securityholder’s name, to
vote, or otherwise to utilize such voting power in the manner contemplated by Section 1.01. The proxy granted by the Securityholder pursuant to this Article 1 is irrevocable and is granted in consideration of Parent entering into this
Agreement and the Acquisition Agreement and 

 incurring certain related fees and expenses; provided, however, the proxy granted by the Securityholder
shall be revoked upon termination of this Agreement in accordance with its terms.
 ARTICLE 2 
 REPRESENTATIONS AND WARRANTIES OF THE SECURITYHOLDER 
 The Securityholder represents and warrants to Parent: 
 Section 2.01. Authorization. The Securityholder has
duly executed and delivered this Agreement, and the execution, delivery and performance by the Securityholder of this Agreement and the consummation by the Securityholder of the transactions contemplated hereby are within the powers and legal
capacity of the Securityholder and have been duly authorized by all necessary action. Assuming accuracy of the representation set forth in Section 3.01, this Agreement is a valid and binding agreement of the Securityholder, enforceable
against the Securityholder in accordance with its terms, except to the extent enforceability may be subject to (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws affecting or relating to
creditors’ rights generally and (ii) general equitable principles (whether considered in a proceeding in equity or at law). 
 Section 2.02. Non-Contravention. The execution, delivery and performance by the Securityholder of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) violate any
law, rule, regulation, judgment, injunction, order or decree applicable to the Securityholder, (ii) require any consent or other action by any Person under, constitute a default under, or give rise to any right of termination, cancellation or
acceleration or to a loss of any benefit to which the Securityholder is entitled in respect of the Securities under any provision of any agreement or other instrument binding on the Securityholder or (iii) result in the imposition of any Lien
on any of the Securities (other than the Lien created hereunder). 
 Section 2.03. Ownership of Securities. The
Securityholder is the record or beneficial owner of the Securities issued and outstanding as of the date hereof, free and clear of any Lien and any other limitation or restriction (including any restriction on the right to vote or otherwise dispose
of the Securities). None of the Securities is subject to any voting trust or other agreement or arrangement with respect to the voting of the Securities. 
 Section 2.04. Total Securities. Except for the Securities set forth on the signature page hereto, the Securityholder does not beneficially own any (i) shares of capital stock or voting
securities of the Company, (ii) securities of the Company convertible into or exchangeable for shares of capital stock or voting securities of the Company or (iii) options or other rights to acquire from the Company any capital stock,
voting securities or securities convertible into or exchangeable for capital stock or voting securities of the Company. 
  

 2 

 ARTICLE 3 
 REPRESENTATIONS AND WARRANTIES OF PARENT 
 Parent represents and warrants to the Securityholder: 

Section 3.01. Authorization. Parent has duly executed and delivered the Acquisition Agreement and this Agreement, and the
execution, delivery and performance by Parent of the Acquisition Agreement and this Agreement and the consummation by Parent of the transactions contemplated thereby and hereby are within the corporate powers of Parent and have been duly authorized
by all necessary corporate action. Each of the Acquisition Agreement and this Agreement constitutes a valid and binding agreement of Parent, enforceable against Parent in accordance with its terms, except to the extent enforceability may be
subject to (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws affecting or relating to creditors’ rights generally and (ii) general equitable principles (whether considered in a
proceeding in equity or at law). 
 ARTICLE 4 
 COVENANTS OF THE SECURITYHOLDER 
 The Securityholder hereby covenants and agrees that so long as this
Agreement is in effect: 
 Section 4.01. No Proxies for or Encumbrances on Securities. Except pursuant to the terms of
this Agreement and the Acquisition Agreement, the Securityholder shall not, without the prior written consent of Parent, directly or indirectly, (i) grant any proxies or enter into any voting trust or other agreement or arrangement with respect
to the voting of any of the Securities or (ii) sell, assign, transfer, encumber or otherwise dispose of, or enter into any contract, option or other arrangement or understanding with respect to the direct or indirect sale, assignment, transfer,
encumbrance or other disposition of, any Securities during the term of this Agreement (other than the deemed disposition of Options upon exercise thereof, the deemed disposition of RSUs upon vesting thereof and the sale of Common Shares received
upon exercise of Options and vesting of RSUs). The Securityholder shall not seek or solicit any such sale, assignment, transfer, encumbrance or other disposition or any such contract, option or other arrangement or understanding and agrees to notify
Parent promptly, and to provide all details requested by Parent, if the Securityholder shall be approached or solicited, directly or indirectly, by any Person with respect to any of the foregoing.
 Section 4.02. Other Offers. The Securityholder shall not directly or indirectly take any action that is prohibited under
Section 3.2 of the Acquisition Agreement with respect to actions to be taken by the Company. The Securityholder will promptly advise and update Parent after receipt by the Securityholder of an Acquisition Proposal.
  

 3 

 ARTICLE 5 
 MISCELLANEOUS 
 Section 5.01. Further Assurances. Parent and the Securityholder will
each execute and deliver, or cause to be executed and delivered, all further documents and instruments and use its best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable
under applicable laws and regulations, to consummate and make effective the transactions contemplated by this Agreement. 
 Section 5.02. Amendments; Termination. Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this
Agreement or in the case of a waiver, by the party against whom the waiver is to be effective. This Agreement shall terminate upon the termination of the Acquisition Agreement, and all rights or obligations of the parties under this Agreement
shall immediately terminate, except as provided in Section 5.12 hereof. 
 Section 5.03. Expenses. All costs and
expenses incurred in connection with this Agreement shall be paid by the party incurring such cost or expense. 
 Section 5.04. Successors and Assigns; Obligations of Securityholder. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns;
provided that no party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other parties hereto. 
 Section 5.05. Governing Law. This Agreement shall be deemed to be made in and in all respects shall be interpreted, construed and
governed by and in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein without regard to its conflict of law principles. The parties hereby irrevocably submit, to the extent permitted by applicable law, to
the jurisdiction of the courts of the Province of Ontario solely in respect of the interpretation and enforcement of the provisions of this Agreement, and of the documents referred to in this Agreement, and in respect of the transactions
contemplated hereby, and hereby waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or
proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement or any such document may not be enforced in or by such courts. The parties hereby consent to and grant any
such court jurisdiction over the person of such parties and over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section 5.11 or in
such other manner as may be permitted by Law shall be valid and sufficient service thereof. 
 Section 5.06. Entire Agreement.
This Agreement, together with the Acquisition Agreement and other documents incorporated therein, appended thereto or contemplated thereby, constitutes the complete, final and exclusive statement of the agreement between the parties pertaining to
the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the parties. 
  

 4 

 Section 5.07. Counterparts; Effectiveness. This Agreement may be signed in any
number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective as between Parent, on the one hand, and the Securityholder,
on the other hand, when each such party shall have received counterparts hereof signed by each such other party. 
 Section 5.08. Severability. If any term, provision or covenant of this Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms,
provisions and covenants of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. 
 Section 5.09. Specific Performance. The parties hereto agree that Parent would suffer irreparable damage in the event any provision of this Agreement is not performed in accordance with the terms hereof and that the
parties shall be entitled to specific performance of the terms hereof in addition to any other remedy to which they are entitled at law or in equity. 
 Section 5.10. Capitalized Terms. Capitalized terms used but not defined herein shall have the respective meanings set forth in the Acquisition Agreement. 
 Section 5.11. Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and
shall be deemed given if delivered personally or sent by overnight courier (providing proof of delivery) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): (i) if to Parent, to
the appropriate address for notice thereto set forth in the Acquisition Agreement and (ii) if to the Securityholder, to the appropriate address set forth underneath the Securityholder’s name on the signature page hereto. 
 Section 5.12. Securityholder Capacity. The Securityholder signs solely in the Securityholder’s capacity as the record holder
or beneficial owner of the Securities and nothing in this Agreement shall limit or affect any actions taken by the Securityholder in the Securityholder’s capacity as an officer or director of the Company. This Section 5.12 shall
survive termination of this Agreement. 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and
year first above written. 
  

			
	 ADVANCED MICRO DEVICES, INC.

		
	 By:
	 	  

	Name:	 	
	Title:	 	

  

			
	
	  

	 [Securityholder’s Name]

	
	Number of Shares:
	Number of Options:
	Number of RSUs:
		
	Address:Commitment Letter

 Exhibit 10.2 
 MORGAN STANLEY SENIOR FUNDING, INC. 
 1585 Broadway 
 New York, New York 10036 
 July 23,
2006 
 Advanced Micro Devices, Inc. 
 One AMD Place 
 Sunnyvale, CA 94088 
 Project Los Angeles 
 Commitment Letter 
 $2,500,000,000 Senior Secured Term Loan Facility 
 Ladies and Gentlemen: 
 Advanced Micro Devices, Inc. (“you” or the “Borrower”) have advised Morgan Stanley Senior Funding, Inc. (“Morgan Stanley”) regarding the proposed acquisition by you of
all of the outstanding capital stock of a publicly traded company code-named “San Antonio” (the “Company”) pursuant to an acquisition agreement between the Borrower and the Company (the “Purchase
Agreement”) whereby the Borrower shall form and organize a direct or indirectly wholly owned subsidiary organized under the laws of Canada or any province thereof which will acquire the outstanding capital stock of the Company (the
“Acquisition”). The Acquisition and the equity and debt financings contemplated hereby are collectively referred to as the “Transaction”. 
 As described on Schedule I to the Fee Letter (defined below), we understand that you currently contemplate that the funding required to effect the
Transaction, to pay the fees and expenses incurred in connection therewith and to provide for the ongoing working capital and general corporate needs of the Borrower and its subsidiaries shall be provided solely from (i) $1,238,000,000 of
common equity (the “New Equity”) of the Borrower to be issued to shareholders of the Company, (ii) the incurrence by the Borrower of a senior secured financing which will be in the form of a “term loan B”
facility in the amount of $2,500,000,000 (the “Term Loan Facility” or the “Facility”) and (iii) aggregate cash on hand at the Borrower and the Company equal to $1,696,000,000 plus the
amount of transaction fees and expenses incurred in connection with the Transactions (other than fees payable to MS in connection with the Transaction). 
 Morgan Stanley & Co., Incorporated (“MS”) has also delivered to you a separate engagement letter dated the date hereof (the “Engagement Letter”) setting forth
the terms on which MS is willing to act in the capacities set forth therein in connection with any Financing Transaction (as defined in the Engagement Letter) that may be consummated at any time up to the first anniversary of the closing date of the
Transaction. 
 We are pleased to commit to provide 100% of the Term Loan Facility subject to and on the terms and conditions set forth
herein and in the summary of terms and conditions attached as Annex I (the “Summary of Terms”). Subject to the following two sentences, it is understood that (i) MS shall act as sole arranger and sole bookrunner for the
Term Loan Facility (in such capacity, the “Senior Sole Arranger”) and (ii) Morgan Stanley shall act as administrative agent for the Term Loan Facility (in such 

 capacity, the “Senior Administrative Agent”). It is further understood that Morgan Stanley shall
be permitted to designate one or more financial institutions as agents or co-agents, as the case may be, with respect to the Term Loan Facility in its sole discretion, and that no titles may be given, or compensation paid, to lenders in respect of
the Term Loan Facility without Morgan Stanley’s consent; provided that you may appoint two additional agents with respect to the Term Loan Facility so long as (i) such additional agents assume no more than an aggregate of 40% of the
commitment for the Term Loan Facility and (ii) such additional agents become party to this letter no later than the fifth business day following the public announcement of the Acquisition. If two additional agents are appointed, both MS and
such additional agents may act as bookrunners for the Term Loan Facility. MS or Morgan Stanley will have “left” placement in any and all marketing materials or other documentation in connection with the Term Loan Facility. Fees payable to
the syndicate for the Term Loan Facility shall be payable from the amounts payable to Morgan Stanley and any other agents as described in the fee letter (the “Fee Letter”) executed simultaneously herewith. 
 Morgan Stanley reserves the right, prior to or after execution of the definitive credit documentation for the Term Loan Facility, to syndicate all or
part of its commitment for the Term Loan Facility to one or more lending institutions (which lending institutions shall be reasonably satisfactory to you (such consent not to be unreasonably withheld or delayed)) that will become parties to the
appropriate definitive credit documentation pursuant to a syndication in respect of the Term Loan Facility to be managed by Morgan Stanley; provided, however that Morgan Stanley and the other two agents appointed by you pursuant to the paragraph
above who become party to this letter shall not be relieved of their obligations to provide the Term Loan Facility until the Term Loan Facility is closed. Morgan Stanley shall commence syndication efforts promptly after the execution of this letter
by you and you agree actively to assist Morgan Stanley in achieving a syndication in respect of the Term Loan Facility that is satisfactory to Morgan Stanley. Such syndication will be accomplished by a variety of means, including direct contact
during the syndication for the Term Loan Facility between your senior management and advisors and senior management and advisors of the Company and the proposed syndicate members for the Term Loan Facility (such members in respect of the Term Loan
Facility being referred to as the “Senior Lenders” or the “Lenders”). To assist Morgan Stanley in its syndication efforts, you hereby agree (a) to provide and cause your advisors to provide, and
to use your commercially reasonable efforts to cause the Company and its advisors to provide, Morgan Stanley and the other relevant syndicate members upon request with all information reasonably deemed necessary by Morgan Stanley to complete
syndication, including but not limited to information and evaluations prepared by you and your advisors or on your behalf relating to the transactions contemplated hereby, (b) to assist Morgan Stanley upon request in the preparation of an
Information Memorandum to be used in connection with the syndication of the Term Loan Facility, (c) to use your commercially reasonable efforts to ensure that the syndication efforts of Morgan Stanley benefit materially from your and the
Company’s existing lending relationships, (d) to make available your senior officers and representatives from time to time and to attend and make presentations regarding the business and prospects of the Borrower and its subsidiaries,
including the Company and its subsidiaries, at a meeting or meetings of Senior Lenders or prospective Senior Lenders and (e) to obtain ratings (prior to the commencement of syndication) for the Term Loan Facility from Moody’s Investors
Service, Inc. (“Moody’s”) and Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc. (“S&P”). You hereby agree that the general bank meeting in respect
of the Term Loan Facility shall be held no later than 30 days prior to the consummation of the Acquisition. In addition, you agree that no financing for you or any of your respective subsidiaries or affiliates (other than the AMD Fab 36
LLC & Co. KG (“Fab 36”) credit facility previously disclosed to Morgan Stanley) shall be syndicated, privately placed or publicly offered to the extent that such financing could reasonably be expected
to have an adverse effect on the syndication of the Term Loan Facility. 
 Please note, however, that the terms and conditions of this
commitment are not limited to those set forth in the Summaries of Terms provided that the conditions to funding of the Term Loan 
  

 2 

 Facility are limited to the conditions described herein and in the Summary of Terms. Those matters that are not covered
or made clear herein or in the Summaries of Terms are subject to mutual agreement of the parties. The terms and conditions of this commitment may be modified only in writing. In addition, this commitment is subject to (a) the preparation,
execution and delivery of mutually acceptable loan documentation for each Facility, including a credit agreement incorporating substantially the terms and conditions outlined herein and in the Term Loan Facility Summary of Terms (the
“Senior Credit Agreement”), (b) (x) except (i) as set forth in the disclosure letter delivered to the Borrower by the Company prior to the date hereof or (ii) as disclosed in the forms, reports and
documents, including financial statements, annual information forms, material change reports and management proxy circulars (collectively, the “Reports”) filed or furnished by the Company under the applicable securities laws
prior to July 23, 2006, for the period from August 31, 2005 to July 22, 2006 there has been no change in the financial condition, business, operations, results of operations, properties, assets or liabilities of the Company and its
subsidiaries or any development or combination of developments that, individually or in the aggregate has had or could reasonably be expected to have a Material Adverse Effect (as defined below), (y) except (i) as set forth in the
disclosure letter delivered to the Company by the Borrower prior to the date hereof or (ii) as disclosed in the Reports filed or furnished by the Borrower under the applicable securities laws prior to July 23, 2006, for the period from
December 25, 2005 to July 22, 2006 there has been no change in the financial condition, business, operations, results of operations, properties, assets or liabilities of the Borrower and its subsidiaries or any development or combination
of developments that, individually or in the aggregate has had or could reasonably be expected to have a Material Adverse Effect (as defined below) and (z) since July 23, 2006, there has been no effect, change or development that,
individually or in the aggregate with other such effects, changes or developments, has had, or could reasonably be expected to have, a Material Adverse Effect, (c) Morgan Stanley’s reasonable satisfaction with the capital and ownership
structure of the Borrower, the Company and their subsidiaries (it being understood and agreed that the capital and ownership structure reflected in the Purchase Agreement dated as of the date hereof is satisfactory to Morgan Stanley) and
(d) the accuracy and completeness of all representations that you make to us and all information that you furnish to us in connection with this commitment, taken as a whole, and your compliance with the terms of this Commitment Letter. Morgan
Stanley’s commitment set forth in this Commitment Letter will terminate on the earliest of (i) consummation of the Acquisition or another transaction or series of transactions in which you or any of your affiliates acquire, directly or
indirectly, all of the capital stock of the Company, (ii) termination of the Purchase Agreement and (iii) 5:00 p.m. (New York City time) on February 24, 2007, unless the Transaction closes on or before such date. Furthermore, if
Morgan Stanley discovers information (whether as a result of the performance of Morgan Stanley’s ongoing business due diligence or otherwise) materially inconsistent with information provided as of the date hereof or not known to it on the date
of this letter which Morgan Stanley reasonably believes is materially negative information with respect to the Transaction or the condition (financial or otherwise), business, properties, operations, results of operations, performance, assets,
liabilities (contingent or otherwise) or value of the Borrower, the Company and their subsidiaries taken as a whole, Morgan Stanley may, in its sole discretion suggest alternative financing amounts or structures that assure adequate protection for
the Lenders. For purposes of this Commitment Letter, “Material Adverse Effect” shall mean a change, effect, event, occurrence, state of facts or development that, individually or in the aggregate with other such changes,
effects, events, occurrences, states of facts or developments, is both material and adverse with respect to the financial condition, business, operations, results of operations, properties, assets or liabilities of the Borrower, the Company and
their subsidiaries taken as a whole; provided, however, that to the extent any effect, event, occurrence, state of facts or development is caused by or results from any of the following, it shall not be taken into account in
determining whether there has been (or whether there could reasonably be expected to be) a Material Adverse Effect: (A) conditions affecting the United States or Canadian economy generally, (B) conditions generally affecting the industries
in which the Borrower or the Company conduct business, (C) any direct or indirect actions of Nvidia Corporation or Intel Corporation, (D) (x) with respect to the Company, conditions directly caused by the actions of the Borrower or
resulting from 
  

 3 

 actions taken in accordance with a request or the consent of the Borrower made after the date hereof and (y) with
respect to the Borrower, conditions directly caused by the actions of the Company or resulting from actions taken in accordance with a request or the consent of the Company made after the date hereof, (E) any delays or cancellation of orders
caused by the announcement of the Purchase Agreement, (F) any change in the market price or trading volume of securities or failure by the Borrower or Company to meet published securities analyst estimates (but not the underlying causes
thereof), (G) material worsening of market conditions caused by acts of terrorism or war occurring after the date hereof, (H) any stockholder litigation arising from allegations of breach of fiduciary duty relating to the Purchase
Agreement, and (I) any losses of employees of the Company or the Borrower caused by the announcement of the Purchase Agreement. Notwithstanding anything in this Commitment Letter, the Summary of Terms, the Fee Letter, the documentation of the
Term Loan Facility or any other letter agreement or other undertaking concerning the financing of the Transaction to the contrary, (i) the only representations relating to the Company, its subsidiaries and its businesses the making and accuracy
of which shall be a condition to availability of the Term Loan Facility on the Closing Date shall be (A) such of the representations made by the Company in the Purchase Agreement as are material to the interests of the Lenders, but only to the
extent that the Borrower has the right to terminate its obligations under the Purchase Agreement as a result of a breach of such representations in the Purchase Agreement and (B) the Specified Representations (as defined below) and
(ii) the terms of the Term Loan Facility documentation shall be in a form such that they do not impair availability of the Term Loan Facility on the Closing Date if the conditions set forth herein and in the Summaries of Terms are satisfied.
“Specified Representations” means the representations and warranties of the Borrower relating to corporate power and authority, the enforceability of the documentation of the Term Loan Facility, security interests, Federal
Reserve margin regulations, the Investment Company Act, no material violation by the Term Loan Facility of organizational documents, agreements, instruments or law, solvency, effectiveness of material regulatory and governmental approvals for the
Term Loan Facility, no litigation purporting to materially adversely affect the Term Loan Facility and status of the Term Loan Facility as senior debt. 
 To induce Morgan Stanley to issue this letter and to continue with its due diligence efforts, you hereby agree that all reasonable out-of-pocket fees and expenses (including the reasonable fees and expenses of one
counsel (in addition to one local counsel in each relevant jurisdiction) and those consultants which have been retained in consultation with AMD) of Morgan Stanley and its affiliates arising in connection with this letter (and its due diligence and
syndication efforts in connection herewith) and in connection with the Term Loan Facility and the other transactions described herein shall be for your account, whether or not the Transaction is consummated, the Term Loan Facility is made available
or definitive credit documents are executed in connection with the Term Loan Facility. In addition, you hereby agree to pay when and as due the fees described in the Fee Letter. 
 You further agree to indemnify and hold harmless each of the Lenders (including, in any event, Morgan Stanley) and each director, officer, employee and
affiliate thereof (each an “Indemnified Person”) from and against any and all actions, suits, proceedings (including any investigations or inquiries), claims, losses, damages, liabilities or expenses of any kind or nature
whatsoever which may be incurred by or asserted against or involve any such Indemnified Person as a result of or arising out of or in any way related to or resulting from this letter, the Transaction, the extension or syndication of the Term Loan
Facility contemplated by this letter, or in any way arise from any use or intended use of this letter or the proceeds of the Term Loan Facility contemplated by this letter, and you agree to reimburse each Indemnified Person upon demand for any legal
or other out-of-pocket expenses incurred in connection with investigating, defending or preparing to defend any such action, suit, proceeding (including any inquiry or investigation) or claim (whether or not Morgan Stanley or any such other
Indemnified Person is a party to any action or proceeding out of which any such expenses arise); provided, however, that you shall not have to indemnify any Indemnified Person against any loss, claim, damage, expense or liability
determined by a court of competent jurisdiction to have resulted from the gross negligence, bad faith or 
  

 4 

 willful misconduct of such Indemnified Person. This letter is issued for your benefit only and no other person or entity
may rely hereon. Neither Morgan Stanley nor any Lender shall be responsible or liable to you, the Company or any other person for consequential damages which may be alleged as a result of this letter. 
 Morgan Stanley reserves the right to employ the services of its affiliates in providing services contemplated by this letter and to allocate, in whole or
in part, to such affiliates certain fees payable to Morgan Stanley in such manner as Morgan Stanley and such affiliates may agree in their sole discretion. You acknowledge that Morgan Stanley may share with any of its affiliates, and such affiliates
may share with Morgan Stanley, any information related to the Transaction, the Borrower, the Company, any of their subsidiaries or any of the matters contemplated hereby in connection with the Transaction, provided that such affiliates agree to the
same confidentiality protections afforded by Morgan Stanley herein. 
 The provisions of the immediately preceding three paragraphs shall
survive any termination of this letter. 
 You represent and warrant that (a) all information (other than the Projections referred to
below) (the “Information”) that has been or will hereafter be made available by or on behalf of you or by any of your representatives in connection with the Transaction and the other transactions contemplated hereby to Morgan
Stanley or any of its affiliates or representatives or to any Lender or any potential Lender is, or in the case of Information made available after the date hereof, will be on the date provided complete and correct in all material respects taken as
a whole and does not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not misleading in light of the circumstances under which such statements
were or are made and (b) all financial projections (the “Projections”), if any, that have been or will be prepared by you or on your behalf or by any of your representatives and made available to Morgan Stanley or any of
its affiliates or representatives or to any Lender, any potential Lender in connection with the Transaction and the other transactions contemplated hereby have been or will be prepared in good faith based upon reasonable assumptions (it being
understood that such projections are subject to significant uncertainties and contingencies, many of which are beyond your control, and that no assurance can be given that any particular projections will be realized). You agree to supplement the
Information and Projections from time to time so that the representations and warranties contained in this paragraph remain complete and correct. 
 In issuing this commitment, Morgan Stanley is relying on the accuracy of the information (other than Projections, forward looking information and information of a general economic or general industry nature) furnished to it by you or on
your behalf or by or on behalf of the Company (to the extent furnished prior to the date hereof, collectively, the “Pre-Commitment Information”). The obligations of Morgan Stanley under this Commitment Letter and of any
Lender that issues a commitment for the Term Loan Facility are made solely for your benefit and may not be relied upon or enforced by any other person or entity. 
 You are not authorized to show or circulate this letter to any other person or entity (other than (i) to your legal advisors in connection with your evaluation hereof, (ii) to the Company and its legal and
financial advisors and (iii) as required by law or stock exchange requirements) until such time as you have accepted this letter as provided in the immediately succeeding paragraph. If the letter is not accepted by you as provided in the
immediately succeeding paragraph, you are to immediately return this letter (and any copies hereof) to the undersigned. This letter may be executed in any number of counterparts, and by the different parties hereto on separate counterparts, each of
which counterpart shall be an original, but all of which shall together constitute one and the same instrument. 
  

 5 

 You acknowledge that Morgan Stanley may provide debt financing, equity capital or other services
(including financial advisory services) to parties whose interests regarding the transactions described herein or otherwise may conflict with your interests. Consistent with Morgan Stanley’s policy to hold in confidence the affairs of its
clients, Morgan Stanley will not furnish confidential information obtained from you or your affiliates to any of its other clients. Furthermore, Morgan Stanley will not use in connection with the transactions contemplated hereby, or furnish to you,
confidential information obtained by Morgan Stanley from any other person. 
 If you are in agreement with the foregoing, please sign and
return to Morgan Stanley (including by way of facsimile transmission) the enclosed copy of this letter, together with the Fee Letter, no later than 11:59 pm, New York time, on July 23, 2006. Our commitment set forth in this letter shall
terminate at the time and on the date referenced in the immediately preceding sentence unless this letter, the Engagement Letter and the Fee Letter are executed and returned by you as provided in such sentence. Upon your acceptance hereof and of the
Engagement Letter and Fee Letter, this Commitment Letter, Engagement Letter and Fee Letter shall be a binding agreement between us. 
 This
letter, the Engagement Letter and the Fee Letter shall be governed by, and construed in accordance with the laws of the State of New York, and any right to trial by jury with respect to any claim, action, suit or proceeding arising out of or
contemplated by this letter and/or the related Fee Letter is hereby waived. The parties hereto hereby submit to the non-exclusive jurisdiction of the federal and New York State courts located in the City of New York in connection with any dispute
related to this letter, the Engagement Letter or the Fee Letter or any matters contemplated hereby or thereby. Delivery of an executed counterpart of a signature page to this Commitment Letter, the Engagement Letter or the related Fee Letter by
telecopier shall be effective as delivery of a manually executed counterpart of this Commitment Letter, Engagement Letter or the related Fee Letter, as the case may be. 
 We hereby notify you that, pursuant to the requirements of the USA Patriot Act, Title III of Pub. L. 107-56 (signed into law on October 26, 2001) (the “Patriot Act”), we are required to
obtain, verify and record information that identifies you, which information includes names and addresses and other information that will allow us to identify you in accordance with the Patriot Act. 
 [The remainder of this page intentionally left blank.] 
  

 6 

			
	Very truly yours,
	
	MORGAN STANLEY SENIOR FUNDING, INC.
		
	By:	 	 /s/ Andrew W. Earls

	Name:	 	Andrew W. Earls
	Title:	 	Vice President

 Agreed to and Accepted this 
 23rd day of July, 2006 
 ADVANCED MICRO DEVICES, INC. 
  

			
	By:	 	 /s/ Robert J. Rivet

	Name:	 	Robert J. Rivet
	Title:	 	Executive Vice President and Chief Financial Officer

 ANNEX I 
 SUMMARY OF CERTAIN TERMS AND CONDITIONS* 
 $2,500,000,000 SENIOR SECURED TERM LOAN FACILITY 
 I. The Parties 
  

			
	Borrower:	  	Advanced Micro Devices, Inc
		
	Senior Sole Arranger and Sole Bookrunner:	  	Morgan Stanley & Co., Incorporated.
		
	Senior Administrative Agent:	  	Morgan Stanley Senior Funding, Inc.
		
	Senior Lenders:	  	Morgan Stanley Senior Funding, Inc. and a syndicate of financial institutions and institutional lenders arranged by Morgan Stanley and reasonably satisfactory to the Borrower (such consent not
to be unreasonably withheld or delayed).
		
	Guarantors:	  	None.

 II. Description of Term Loan Facility 
  

			
	Term Loan Facility:	  	$2,500,000,000 Term Loan B Facility.
		
	Maturity and Amortization:	  	The final maturity of the Term Loan Facility shall be the date which occurs seven years after the Closing Date. The loans under the Term Loan Facility (the “Term
Loans”) shall be repaid during the final year of the Term Loan Facility in equal quarterly amounts, subject to amortization of approximately 1% per year prior to such final year.
		
	Use of Proceeds:	  	The Term Loans shall only be utilized (x) to finance, in part, the Transaction, (y) to pay fees and expenses incurred in connection with the Transaction and (z) for general corporate
purposes.
		
	Availability:	  	Term Loans may only be borrowed on the Closing Date. No amount of Term Loans once repaid may be reborrowed.

 III. Terms Applicable to the Term Loan Facility 
  

			
	Closing Date:	  	The date on or before February 24, 2007 on which the conditions precedent to the initial extension of credit under Term Loan Facility shall be satisfied (such date being the
“Closing Date”).
		
	Security:	  	The Borrower shall grant the Senior Administrative Agent and the Senior Lenders a valid and perfected first priority (subject to the granting of an

	*	Capitalized terms used herein and not defined herein shall have the meanings provided in the commitment letter (the “Commitment Letter”) to which this
summary is attached. 

  

 I-1 

					
		  	equal and ratable security interest to the holders of the Existing Senior Notes to the extent required
by the terms of the related indenture and certain exceptions to be set forth
in the loan
documentation) lien and security interest in all of the following:
			
		  	(a)	 	All shares of capital stock of (or other ownership interests in) and intercompany debt of each of the subsidiaries listed on Exhibit A hereto as well as each of the Borrower’s future
restricted material domestic subsidiaries and material first tier foreign subsidiaries (it being understood that no security interest will be granted in the capital stock of Spansion, AMD Fab 36 LLC & Co KG, AMD Fab 36 Holding GmbH, AMD Fab 36
Admin GmbH, AMD Fab 36 LLC or the IP Subsidiary (defined below)), limited, in the case of any controlled foreign corporation under Section 957 of the Internal Revenue Code, to 66% of the voting stock of such entity (or such greater percentage as
would not result in a material tax liability).
			
		  	(b)	 	All accounts receivable owned by the Borrower and AMD International Sales & Service, Ltd. and any other present or future domestic subsidiary of the Borrower.
			
		  	(c)	 	All proceeds and products of the property and assets described in clauses (a) and (b) above.
			
		  	(d)	 	Any proceeds from the direct or indirect sale of the equity interests of Spansion and a collateral account into which the Borrower will covenant to deposit, or cause to be deposited, any of such
proceeds.
		
	Interest Rates:	  	At the option of the Borrower, Term Loans may be maintained from time to time as (x) Base Rate
Loans, which shall bear interest at the Applicable Margin in excess of the Base Rate
in effect from
time to time, or (y) Eurodollar Loans, which shall bear interest at the Applicable Margin in excess
of the Eurodollar Rate (adjusted for maximum reserves) as determined by the Senior
Administrative Agent for the respective
interest period.
		
		  	“Base Rate” shall mean the higher of (x) 1/2 of 1% in excess of the federal funds rate and (y) the
rate that the Senior Administrative Agent announces from
time to time as its prime or base
commercial lending rate, as in effect from time to time.
		
		  	The “Applicable Margin” means at any time, an amount per annum based upon the rating of the
Term Loan Facility as of the Closing Date in accordance with
the grid set forth on Schedule II to
the Fee Letter.
		
		  	During the continuance of any default under the loan documentation, the Applicable Margin on all
obligations owing under the loan documentation shall increase by 2% per
annum.

  

 I-2 

			
		  	Interest periods of 1, 2, 3 and 6 months shall be available in the case of Eurodollar Loans; provided that Eurodollar Loans made on the Closing Date shall have one month interest periods
only.
		
		  	Interest in respect of Base Rate Loans shall be payable quarterly in arrears on the last business day of each quarter. Interest in respect of Eurodollar Loans shall be payable in arrears at the
end of the applicable interest period and every three months in the case of interest periods in excess of three months. Interest will also be payable at the time of repayment of any Term Loans, and at maturity. All interest and commitment fee and
other fee calculations shall be based on a 360 day year (or 365 or 366 days, as the case may be, in the case of Base Rate Loans).
		
	 Senior Sole Arranger and
 Senior Administrative
Agent
 Fees:
	  	  
 The Senior Sole Arranger and the Senior Administrative Agent shall receive
such fees as have been separately agreed upon with the Borrower.

		
	Voluntary Prepayment:	  	The Borrower may, upon at least one business day’s notice in the case of Base Rate Loans and three business days’ notice in the case of Eurodollar Loans, prepay, in full or in part,
the Term Loans without premium or penalty; provided, however, that each partial prepayment shall be in an amount of $5,000,000 or an integral multiple of $1,000,000 in excess thereof; provided further that any such prepayment of
Eurodollar Loans shall be made together with reimbursement for any funding losses of the Lenders resulting therefrom.
		
	Mandatory Prepayment and Commitment Reduction:	  	All net cash proceeds (a) from sales of property and assets of the Borrower and its subsidiaries (including the sale of the equity interests of Spansion but excluding sales of inventory in the
ordinary course of business and other exceptions to be agreed and subject to a reinvestment provision to be negotiated (which reinvestment rights shall not apply to proceeds of the sale of the equity interests of Spansion)), (b) of Extraordinary
Receipts (to be defined in the loan documentation and to exclude cash receipts in the ordinary course of business and other exceptions to be agreed) and (c) from the issuance after the Closing Date of additional debt and equity of the Borrower and
its subsidiaries (excluding the New Equity and subject to other exceptions to be agreed), and 50% of Excess Cash Flow (to be defined in the loan documentation) of the Borrower and its subsidiaries shall be applied to prepay the Term Loans, ratably
to the principal repayment installments of the Term Loans.
		
	Documentation:	  	Morgan Stanley’s commitment will be subject to the negotiation, execution and delivery of definitive financing agreements (and related security documentation, guaranties, etc.) consistent
with the terms of this letter, in each case prepared by counsel to Morgan Stanley.

  

 I-3 

					
	 Conditions Precedent
 to Initial
Extension
 of Credit:
	  	  
 Those customarily found in credit agreements for similar secured financings and others appropriate
in the
judgment of Morgan Stanley for the Transaction, including, without limitation, those
specified in Annex II.

		
	 Representations and
 Warranties:
	  	  
 Those customarily found in credit agreements for similar secured financings and others appropriate
in
the judgment of Morgan Stanley for the Transaction, including, without limitation, absence of
any material adverse change in the business, condition (financial or otherwise), operations,
performance or properties of the Borrower and its
subsidiaries, taken as a whole.

		
	Covenants:	  	Those affirmative and negative covenants (applicable to the Borrower and its subsidiaries)
customarily found in credit agreements for similar secured financings or, in the case of
the negative
covenants, substantially similar to those in the indenture for the Existing Senior Notes (as defined
below) and others appropriate in the reasonable judgment of Morgan Stanley for the Transaction
including, without limitation,
the following:
			
		  	(a)	 	Affirmative Covenants - (i) Compliance with laws and regulations (including, without limitation, ERISA and environmental laws); (ii) payment of taxes and other obligations; (iii)
maintenance of appropriate and adequate insurance; (v) preservation of corporate existence, rights (charter and statutory), franchises, permits, licenses and approvals; (iv) visitation and inspection rights; (v) keeping of proper books in accordance
with generally accepted accounting principles; (vi) maintenance of properties; (vii) performance of leases, related documents and other material agreements; (viii) use of proceeds; (ix) further assurances as to perfection and priority of security
interests; and (x) customary financial and other reporting requirements (including, without limitation, audited annual financial statements and quarterly unaudited financial statements, in each case prepared on a consolidated and a consolidating
basis, notices of defaults, compliance certificates, annual business plans and forecasts, reports to shareholders and other creditors and other business and financial information as any Lender shall reasonably request).
			
		  	(b)	 	Negative Covenants - Restrictions on (i) liens (other than existing liens, liens securing the Term Loan Facility and liens securing the outstanding 7.75% Senior Notes Due 2012 (the
“Existing Senior Notes”) to the extent required by the terms thereof); (ii) debt, guaranties or other contingent obligations (including, without limitation, the subordination of all intercompany indebtedness on terms
satisfactory to the Lenders); (iii) mergers and consolidations; (iv) sales, transfers and other dispositions of assets (other than sales of inventory in the ordinary course of business and the transfer of intellectual

  

 I-4 

					
		  		 	 property of the Company to the Borrower or a direct wholly-owned restricted special purpose subsidiary of the Borrower (the “IP
Subsidiary”)) ; (v) loans, acquisitions, joint ventures and other investments; (vi) dividends and other distributions to stockholders; (vii) creating new subsidiaries; (viii) becoming a general partner in any partnership; (ix) repurchasing
shares of capital stock; (x) prepaying, redeeming or repurchasing debt; (xi) capital expenditures; (xii) granting negative pledges; (xiii) changing the nature of its business; (xiv) amending organizational documents, or amending or otherwise
modifying any debt or related document; (xv) transactions with affiliates; (xvi) change in passive holding company status or special purpose nature of the IP Subsidiary; and (xvii) changing accounting policies or reporting practices; in each of the
foregoing cases, with such exceptions as may be agreed upon in the loan documentation.

			
		  	(c)	 	Financial Covenants – None.
		
	Events of Default:	  	Those customarily found in credit agreements for similar secured financings and others appropriate
in the judgment of Morgan Stanley for the Transaction, including, without
limitation, (a) failure to
pay principal when due, or to pay interest or other amounts within two business days after the same
becomes due, under the loan documentation; (b) any representation or warranty proving to have
been materially
incorrect when made or confirmed; (c) failure to perform or observe covenants set
forth in the loan documentation within a specified period of time, where customary and
appropriate, after notice or knowledge of such failure; (d) cross-defaults
to other indebtedness in an
amount to be agreed in the loan documentation; (e) bankruptcy and insolvency defaults (with grace
period for involuntary proceedings); (f) monetary judgment defaults in an amount to be agreed in
the loan
documentation and nonmonetary judgment defaults that could reasonably be expected to
have a Material Adverse Effect; (g) impairment of loan documentation or security; (h) change of
ownership or operating control; and (i) standard ERISA
defaults.
		
	Expenses:	  	The Borrower shall pay all of the Senior Administrative Agent’s and the Senior Sole Arranger’s
reasonable due diligence, syndication (including printing, distribution
and bank meetings),
transportation, computer, duplication, appraisal, audit, insurance, consultant, search, filing and
recording fees and all other reasonable out of pocket expenses incurred by the Senior
Administrative Agent or the Senior
Sole Arranger (including the fees and expenses of one counsel
(in addition to one local counsel in each relevant jurisdiction) for the Senior Sole Arranger),
whether or not any of the transactions contemplated hereby are consummated, as well
as all
expenses of the Senior Administrative Agent in connection with the administration of the loan
documentation. The Borrower shall also pay the expenses of the Senior Administrative Agent, the
Senior Sole Arranger and the Senior Lenders
in connection with the enforcement of any of the loan
documentation.

  

 I-5 

			
	Indemnity:	  	The Borrower will indemnify and hold harmless the Senior Administrative Agent, the Senior Sole Arranger, each Senior Lender and each of their affiliates and their officers, directors,
employees, agents and advisors from claims and losses relating to the Transaction or the Term Loan Facility, except to the extent judicially determined to have resulted from the gross negligence or willful misconduct of the
indemnitee.
		
	Required Lenders:	  	Senior Lenders holding loans and commitments representing more than 50% of the aggregate amount of loans and commitments under the Term Loan Facility.
		
	 Waivers &
 Amendments:
	  	
  
 Amendments and waivers of the provisions of the loan
agreement and other definitive credit documentation shall require the approval of the Required Lenders, except that (x) the consent of all affected Senior Lenders shall be required with respect to (i) increases in commitment amounts, (ii) reductions
of principal, interest, or fees, (iii) extensions of, the final maturity date and (iv) changes to the order of applications of prepayments and (y) the consent of all affected Senior Lenders shall be required with respect to releases of all or
substantially all of the Collateral.

		
	 Assignments and
 Participations:
	  	
  
 Assignments may be non-pro rata and must be to Eligible
Assignees (to be defined in the definitive loan documentation) and, in each case other than an assignment to a Lender or an assignment of the entirety of a Lender’s interest in the Term Loan Facility, in a minimum amount equal to $1 million.
Each Senior Lender will also have the right, without consent of the Borrower or the Senior Administrative Agent, to assign (i) as security all or part of its rights under the loan documentation to any Federal Reserve Bank and (ii) all or part of its
rights or obligations under the loan documentation to any of its affiliates. No participation shall include voting rights, other than for reductions or postponements of amounts payable or releases of all or substantially all of the
collateral.

		
	Taxes:	  	All payments to be free and clear of any present or future taxes, withholdings or other deductions whatsoever (other than income taxes in the jurisdiction of the Senior Lender’s applicable
lending office). The Senior Lenders will use reasonable efforts (consistent with their respective internal policies and legal and regulatory restrictions and so long as such efforts would not otherwise be disadvantageous to such Senior Lenders) to
minimize to the extent possible any applicable taxes and the Borrower will indemnify the Senior Lenders and the Senior Administrative Agent for such taxes paid by the Senior Lenders or the Senior Administrative Agent.
		
	Miscellaneous:	  	Standard yield protection (including compliance with risk based capital guidelines, increased costs, payments free and clear of withholding taxes and interest period breakage indemnities),
eurodollar illegality and similar provisions, defaulting lender provisions, waiver of jury trial and submission to jurisdiction provisions.

  

 I-6 

			
	Governing Law:	  	New York.
		
	Counsel for Morgan Stanley:	  	Skadden, Arps, Slate, Meagher & Flom LLP.

  

 I-7 

 EXHIBIT A TO 
 ANNEX I 
 Pledged Subsidiaries 
  

	1.	AMD US Finance, Inc. 

  

	2.	AMD Saxony Holding GmbH 

  

	3.	AMD Saxony LLC 

  

	4.	AMD International Sales & Service, Ltd. 

  

	5.	Advanced Micro Devices (Singapore) Pte Ltd 

  

	6.	Advanced Micro Devices Sdn.Bhd. 

 ANNEX II 
 CONDITIONS PRECEDENT 
 $2,500,000,000 SENIOR SECURED TERM LOAN FACILITY 
 [Capitalized terms not otherwise defined herein have the same meanings as 
 specified therefor in the Commitment Letter to which this Annex II is attached] 
  

					
	 Conditions Precedent
	  		 	
	 to Closing:
	  	The closing and the initial extension of credit under the Term Loan Facility will be subject to satisfaction (or
waiver) of the following conditions precedent:
			
		  	(i)	 	The final terms and conditions of the Transaction, including, without limitation, all material legal and tax aspects thereof, shall be as described in the Commitment Letter and otherwise
consistent with the description thereof received in writing as part of the Pre-Commitment Information or otherwise reasonably satisfactory to the Lenders. The Lenders shall be reasonably satisfied with (x) the Purchase Agreement (including all
schedules and exhibits thereto), which shall provide for an aggregate cash purchase price not in excess of $5,389,000,000 and (y) all other agreements, instruments and documents relating to the Transaction; and the Purchase Agreement and such other
agreements, instruments and documents relating to the Transaction shall not be altered, amended or otherwise changed or supplemented or any condition therein waived, in each case in any manner materially adverse to the Lenders, without the prior
written consent of the Administrative Agent (it being agreed that the draft Purchase Agreement dated July 23, 2006 is satisfactory to the Administrative Agent). The Acquisition shall have been consummated substantially in accordance with the terms
of the Purchase Agreement and in compliance with applicable law.
			
		  	(ii)	 	The execution and delivery of definitive documentation with respect to the Term Loan Facility consistent with the Summary of Terms and the Commitment Letter.
			
		  	(iii)	 	All of the capital stock of the Borrower’s restricted subsidiaries shall be owned by the Borrower or one or more of the Borrower’s subsidiaries (except, with respect to foreign
subsidiaries, for insignificant interests statutorily required to be owned by another person), in each case free and clear of any lien, charge or encumbrance not permitted under the loan documentation; the Lenders shall have a valid and perfected
first priority (subject to certain exceptions to be set forth in the loan documentation) lien and security interest in such capital stock and in the other collateral referred to under the section “Security” above; all
filings, recordations and searches necessary or desirable in connection with such liens and security interests

  

 II-1 

					
	 	 	 	  	shall have been duly made; and all filing and recording fees and taxes shall have been duly paid. To the
extent required by the terms of the Borrower’s Existing Senior Notes, the
Existing Senior Notes shall
be equally and ratably secured by such of the collateral as required by the related indenture. The
Lenders will agree that upon distribution of the proceeds from the sale of collateral, such proceeds
allocable to
any of the Term Loans under the security documentation shall be applied in a manner such
that all of the Lenders shall share ratably in such application.
			
		 	(iv)	  	There shall exist no action, suit, investigation, litigation or proceeding pending or threatened in any court or before any arbitrator or governmental or regulatory agency or authority that (a)
could reasonably be expected to (i) have a material adverse effect on the business, condition (financial or otherwise), operations, performance or properties of the Borrower, the Company and their subsidiaries, taken as a whole, (ii) adversely
affect the ability of the Borrower to perform its obligations under the loan documentation for each Facility or (iii) adversely affect the rights and remedies of the Administrative Agent and the Lenders under the loan documentation (collectively, a
“Material Adverse Effect”) or (b) purports to adversely affect the Transaction or the Term Loan Facility.
			
		 	(v)	  	All material governmental and third party consents and approvals necessary in connection with the Transaction and the Term Loan Facility shall have been obtained (without the imposition of any
conditions that are not reasonably acceptable to the Lenders) and shall remain in effect; all applicable waiting periods shall have expired without any materially adverse action being taken by any competent authority; and no law or regulation shall
be applicable in the judgment of the Lenders that restrains, prevents or imposes materially adverse conditions upon the Transaction or the Term Loan Facility.
			
		 	(vi)	  	All loans made by the Lenders to the Borrower or any of its affiliates shall be in full compliance with the Federal Reserve’s Margin Regulations.
			
		 	(vii)	  	The Borrower shall have delivered certificates, in form and substance satisfactory to the Lenders, attesting to the Solvency (as hereinafter defined) of the Borrower, individually and together
with its subsidiaries, taken as a whole, immediately before and immediately after giving effect to the Transaction, from its chief financial officer. As used herein, the term “Solvency” of any person means (i) the fair value
of the property of such person exceeds its total liabilities (including, without limitation, contingent liabilities), (ii) the present fair saleable value of the assets of such person is not less than the amount that will be required to pay its
probable liability on its debts as they

  

 II-2 

					
	 	  	 	  	become absolute and matured, (iii) such person does not intend to, and does not believe that it will,
incur debts or liabilities beyond its ability to pay as such debts and liabilities mature
and (iv) such
person is not engaged, and is not about to engage, in business or a transaction for which its property
would constitute an unreasonably small capital.
			
		  	(viii)	  	The Lenders shall have received annual financial statements as of the end of the most recently completed three fiscal years, interim financial statements dated the end of the most recent fiscal
quarter for which financial statements are available (or, in the event the Lenders’ due diligence review reveals material changes since such financial statements, as of a later date within 45 days of the Closing Date), pro forma consolidated
financial statements as to the Borrower and its subsidiaries, and forecasts prepared by management of the Borrower, in a form satisfactory to the Lenders, of balance sheets, income statements and cash flow statements on a quarterly basis for the
first year following the Closing Date and on an annual basis for each year thereafter during the term of the Term Loan Facility.
			
		  	(ix)	  	The Lenders under the Term Loan Facility shall have received (a) customary opinions of counsel (including local counsel) for the Borrower as to the transactions contemplated hereby and (b) such
corporate resolutions, certificates (including insurance certificates) and other documents as the Lenders under Term Loan Facility shall reasonably request.
			
		  	(x)	  	There shall exist no default under any of the loan documentation for the Term Loan Facility, and the representations and warranties of the Borrower and each of its subsidiaries therein shall be
true and correct immediately prior to, and after giving effect to, the initial extension of credit under the Term Loan Facility.
			
		  	(xi)	  	All accrued fees and expenses of the Senior Administrative Agent, the Senior Sole Arranger and the Senior Lenders (including the fees and expenses of one counsel (including one local counsel in
each relevant jurisdiction) for the Senior Administrative Agent and the Senior Sole Arranger and local counsel for the Senior Lenders) shall have been paid.
			
		  	(xii)	  	The Company’s existing credit facility shall have been, or concurrently with the extension of credit under the Facility shall be, terminated and all amounts outstanding thereunder, if any
shall have been paid off and all liens shall have been released pursuant to a termination letter reasonably satisfactory to the Senior Administrative Agent.

  

 II-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]